-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

A clinical overview of REZLIDHIA (olutasidenib): A Newly Approved Therapy for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation

Sponsor: Rigel Pharmaceuticals
Program: Product Theaters
Monday, December 12, 2022: 12:15 PM-1:15 PM
Hall J - Theater 4 (Ernest N. Morial Convention Center)
Aaron Sheppard, PhD, Rigel Pharmaceuticals
No relevant conflicts of interest to declare.
For in-person participants only
See more of: Product Theaters